Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 20Breast Neoplasms 10Fallopian Tube Neoplasms 9Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Lung Neoplasms 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Hereditary Breast and Ovarian Cancer Syndrome 2Testicular Neoplasms 1Stage IV Fallopian Tube Cancer AJCC v6 and v7 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Neoplasms, Unknown Primary 1Liver Failure 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Brenner Tumor 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 14Specimen Handling 8Docetaxel 8olaparib 7Nivolumab 7Gemcitabine 7Trastuzumab 6Paclitaxel 6rucaparib 5Magnetic Resonance Spectroscopy 5Early Intervention, Educational 5Biopsy 5Standard of Care 4Cyclophosphamide 4Carboplatin 4tisotumab vedotin 3talazoparib 3pertuzumab 3durvalumab 3atezolizumab 3Taxes 3Surveys and Questionnaires 3Sirolimus 3Radiotherapy 3Psychiatric Rehabilitation 3Methods 3Irinotecan 3Immunoglobulin G 3Fulvestrant 3Educational Status 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × veliparib × Gynecologic × Clear all
NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡